Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Major Depressive Disorder Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

24 Aug, 2022, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

Major depressive disorder pipeline constitutes 60+ key companies continuously working towards developing 75+ major depressive disorder treatment therapies, analyzes DelveInsight

LAS VEGAS, Aug. 24, 2022 /PRNewswire/ -- DelveInsight's 'Major Depressive Disorder Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline major depressive disorder therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the major depressive disorder pipeline domain.

Key Takeaways from the Major Depressive Disorder Pipeline Report

  • DelveInsight's major depressive disorder pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for major depressive disorder treatment. 
  • Leading major depressive disorder companies such as GH Research, Praxis Precision Medicines, AbbVie, Luye Pharma Group, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, XWPharma, Reviva Pharmaceuticals, Gate Neurosciences, Sirtsei Pharmaceuticals Seelos Therapeutics, Chase Therapeutics, Clexio Biosciences Ltd, VistaGen Therapeutics, Neuralstem, BioLite, Neurocrine Biosciences, MindMed, BioGen, Alector and Chase Therapeutics, Cybin  others are evaluating novel major depressive disorder treatment drugs candidate to improve the treatment landscape.
  • Key major depressive disorder pipeline therapies in various stages of development include AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 and others.
  • In August 2022, Relmada Therapeutics announced the Food and Drug Administration (FDA) granted Fast Track designation to REL-1017 (esmethadone) as a monotherapy for the treatment of major depressive disorder (MDD). REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker. The investigational treatment is administered orally once daily and is designed to target hyperactive GluN1-GluN2D NMDAR channels while maintaining physiological glutamatergic neurotransmission.
  • In June 2022, Cybin received FDA IND Clearance for its Phase I/IIa clinical trial evaluating CYB003 for the potential treatment of Major Depressive Disorder.
  • In June 2022,  Biogen and Sage Therapeutics announced that the Phase III SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Women treated with zuranolone 50 mg (n=98) demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to placebo (n=97) as measured by a change from baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score.
  • In October 2021, Small Pharma granted Fast-Track Designation from the UK regulator for SPL026 DMT-Assisted therapy for Major Depressive Disorder.
  • In October 2021, Chase Therapeutics announced $20 million Series B financing to advance clinical trials in parkinson's disease and Major Depressive Disorder. The proceeds of the Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson's Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson's Disease.

Request a sample and discover the recent advances in major depressive disorder treatment @Major Depressive Disorder Pipeline Report

The major depressive disorder pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage major depressive disorder drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the major depressive disorder pipeline landscape.

Major Depressive Disorder Overview

Major depressive disorder (MDD), commonly known as clinical depression, is a serious medical condition that can greatly impact life. It impacts mood, behavior, and physical functions such as eating and sleep. The exact major depressive disorder causes are unknown. However, several variables can raise the chances of acquiring the condition. A combination of genes and stress can change brain chemistry and impair mood stability.

Although depression can occur only once in a lifetime, most people have several episodes. The major depressive disorder symptoms occur most of the day, nearly every day. The common depressive disorder symptoms include sadness, anxiety, trouble thinking, unexplained physical problems, restlessness, and others. No blood tests, X-rays, or other laboratory tests are available for major depressive disorder diagnosis. However, the doctor may do blood tests to assist in discovering any other medical disorders that have symptoms similar to those of depression.

Find out more about MDD treatment @Major Depressive Disorder Medication 

A snapshot of the Major Depressive Disorder Pipeline Drugs mentioned in the report:

Drugs

Company

Phase 

MoA

RoA

SAGE-217

Sage Therapeutics

Pre-registration

GABA A receptor modulators

Oral

REL-1017

Relmada Therapeutics, Inc

Phase III

NMDA receptor antagonists

Oral

Seltorexant

Minerva Sciences 

Phase III

Orexin receptor type 2 antagonists

Oral

Lumateperone

Intra-Cellular Therapies

Phase III

Dopamine D2 receptor modulators

Oral

SP-624

Sirtsei Pharmaceuticals, Inc.

Phase II

NA

Oral

SPL026

Small Pharma

Phase II

Serotonin 2A receptor agonists

Intravenous

PDC-1421

BioLite Inc

Phase II

Norepinephrine plasma membrane transport protein inhibitors

Oral

TAK 653

Takeda

Phase II

AMPA receptor modulators

Oral

PH 10

Pherin Pharmaceuticals

Phase II

Chemoreceptor cell stimulants

Intranasal

XW 10508

XWPharma

Phase I

AMPA receptor agonists

Oral

Learn more about the novel and emerging major depressive disorder pipeline therapies @Major Depressive Disorder Clinical Trials

Major Depressive Disorder Therapeutics Assessment

The major depressive disorder pipeline report proffers an integral view of the major depressive disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Major Depressive Disorder Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular
  • Therapeutics Assessment By Molecule Type: Bispecific antibody, Peptide, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: GABA A receptor modulators, NMDA receptor antagonists, Orexin receptor type 2 antagonists, Serotonin 2A receptor agonists, Norepinephrine plasma membrane transport protein inhibitors, Sortilin inhibitors, Serotonin 2A receptor agonists, Dopamine D2 receptor agonists; Dopamine D3 receptor agonists, Chemoreceptor cell stimulants
  • Key Major Depressive Disorder Companies: GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, XWPharma, Reviva Pharmaceuticals,Gate Neurosciences, Sirtsei Pharmaceuticals Seelos Therapeutics, Chase Therapeutics,Clexio Biosciences Ltd, VistaGen Therapeutics, Neuralstem, BioLite,Neurocrine Biosciences, MindMed, BioGen, Alector and Chase Therapeutics, Cybin, and others
  • Key Major Depressive Disorder Pipeline Therapies: AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120,  Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 , and others.

Dive deep into rich insights for drugs for MDD treatment, visit @New Drug for Major Depressive Disorder Treatment 

Table of Contents

1.

Major Depressive Disorder Pipeline Report Introduction

2.

Major Depressive Disorder Pipeline Report Executive Summary

3.

Major Depressive Disorder Pipeline: Overview

4.

Analytical Perspective In-depth Commercial Assessment

5.

Major Depressive Disorder Clinical Trial Therapeutics

6.

Major Depressive Disorder Pipeline: Late Stage Products (Pre-registration)

7.

SAGE-217: Sage Therapeutics

8.

Major Depressive Disorder Pipeline: Late Stage Products (Phase III)

9.

REL-1017: Relmada Therapeutics

10.

Major Depressive Disorder Pipeline: Mid Stage Products (Phase II)

11.

SP-624: Sirtsei Pharmaceuticals

12.

Major Depressive Disorder Pipeline: Early Stage Products (Phase I)

13.

XW 10508: XW Pharma

14.

Major Depressive Disorder Pipeline Therapeutic Assessment

15.

Inactive Products in the Major Depressive Disorder Pipeline

13.

Company-University Collaborations (Licensing/Partnering) Analysis

14.

Key Companies

15.

Key Products in the Major Depressive Disorder Pipeline

16.

Unmet Needs

17.

Market Drivers and Barriers

18.

Future Perspectives and Conclusion

19.

Analyst Views

20.

Appendix

For further information on the major depressive disorder pipeline therapeutics, reach out @Major Depressive Disorder Drugs

Related Reports

Major Depressive Disorder Market

Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key major depressive disorder companies including GH Research, Praxis Precision Medicines, AbbVie, among others.

Major Depressive Disorder Epidemiology Forecast

Major Depressive Disorder Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted major depressive disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Treatment-resistant Depression Pipeline

Treatment-resistant Depression Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key treatment-resistant depression companies, including Axsome Therapeutics, Sage Therapeutics, AbbVie, among others.

Treatment-resistant Depression Market

Treatment-resistant Depression Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key treatment-resistant depression companies, including Axsome Therapeutics, Sage Therapeutics, AbbVie, among others.

Treatment-resistant Depression Epidemiology Forecast

Treatment-resistant Depression Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted treatment-resistant depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bipolar Depression Pipeline

Bipolar Depression Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including Vanda Pharmaceuticals, Sunovion, Pear Therapeutics, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

Latest Healthcare Blogs

Major Depression Disorder Treatment Market

Major Depressive Disorder Market Outlook

Treatment-resistant Depression Treatment Landscape

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging ...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.